Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation
Journal
The Journal of infectious diseases
Journal Volume
208
Journal Issue
9
Date Issued
2013-11-01
Author(s)
Szarewski, Anne
Skinner, S Rachel
Garland, Suzanne M
Romanowski, Barbara
Schwarz, Tino F
Apter, Dan
Paavonen, Jorma
Del Rosario-Raymundo, M Rowena
Teixeira, Julio C
De Carvalho, Newton S
Castro-Sanchez, Maria
Castellsagué, Xavier
Poppe, Willy A J
De Sutter, Philippe
Huh, Warner
Chatterjee, Archana
Tjalma, Wiebren A
Ackerman, Ronald T
Martens, Mark
Papp, Kim A
Bajo-Arenas, Jose
Harper, Diane M
Torné, Aureli
David, Marie-Pierre
Struyf, Frank
Lehtinen, Matti
Dubin, Gary
Abstract
Public Health England has reported a decrease of up to 20.8% in new diagnoses of external genital warts (GWs) among women aged <19 years since the national vaccination program with the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine began in 2008. A post hoc analysis of the phase III PATRICIA (PApilloma TRIal against Cancer In young Adults) trial (NCT00122681) was performed to ascertain whether protection against low-risk HPV types was apparent.
Subjects
HPV; HPV vaccine; genital warts; human papillomavirus
Type
journal article